Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 17/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033987 | 1.00 | SLC10A1 (0.47) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL30035645 | 0.90 | SLC10A1 (0.45) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL19332126 | 0.90 | SLC10A1 (0.45) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL21889666 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL22545623 | 0.85 | SLC10A1 (0.49) | SLC10A1NPC1POLBMAPTRAB9A | |
| SCHEMBL19332348 | 0.85 | SLC10A1 (0.44) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL21889751 | 0.84 | SLC10A1 (0.45) | SLC10A1TSHRNPC1POLBMAPT | |
| SCHEMBL19332096 | 0.84 | SLC10A1 (0.47) | SLC10A1TSHR | |
| SCHEMBL19347059 | 0.83 | SLC10A1 (0.49) | SLC10A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL21889664 | 0.83 | SLC10A1 (0.45) | SLC10A1TSHRNPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| CN-109153640-B | Eliminating hepatitis B virus with antiviral agent | 埃默里大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3426633-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | Emory University (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | SLC10A1 2/4885TSHR 3180/4885NPC1 32/4885 |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | SLC10A1 2/4885TSHR 3180/4885NPC1 32/4885 |
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | SLC10A1 2/4885TSHR 3180/4885NPC1 32/4885 |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | SLC10A1 2/4885TSHR 3180/4885NPC1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.